Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Ian Lipkin, Guillermina Lozano

Premium

Ian Lipkin has been awarded Villanova University's 2014 Mendel Medal.

Since 1929, Villanova has given the medal to scientists in recognition of their accomplishments. Lipkin is a professor of epidemiology at Columbia University's Mailman School of Public Health, and director of the school's Center for Infection and Immunity.

He is credited with the discovery of the implication of West Nile virus as the cause of encephalitis in North America in 1999, the invention of MassTag PCR, and the first panmicrobial microarray.


Guillermina Lozano has been named to the board of directors of the American Association for Cancer Research for its 2014-2017 term.

Lozano is professor and chair of the department of genetics, co-director of the genetically engineered mouse facility, co-director of the Center for Genetics and Genomics, co-director of the sequencing and microarray facility, and co-director of the cancer genetics and epigenetics program at the University of Texas MD Anderson Cancer Center.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.